Angiotensin 1-7
Angiotensin-(1-7)
Overview
Angiotensin 1-7 is a seven-amino-acid peptide component of the renin-angiotensin system (RAS) that acts as a counter-regulatory axis to the classical angiotensin II pathway. While angiotensin II promotes vasoconstriction inflammation and fibrosis angiotensin 1-7 has opposing vasodilatory anti-inflammatory and anti-fibrotic effects. It has been studied extensively for cardiovascular protection kidney disease COVID-19 complications and metabolic syndrome. Interest in angiotensin 1-7 increased dramatically during the COVID-19 pandemic when ACE2 — the enzyme that produces angiotensin 1-7 — was identified as the SARS-CoV-2 receptor.
Mechanism of Action
Angiotensin 1-7 is produced from angiotensin II by ACE2 (angiotensin-converting enzyme 2) and acts through the Mas receptor — a G-protein-coupled receptor that mediates its protective cardiovascular and anti-inflammatory effects. Mas receptor activation opposes angiotensin II signaling by promoting nitric oxide release causing vasodilation reducing oxidative stress and inhibiting NF-κB-mediated inflammation. In the kidney angiotensin 1-7 reduces fibrosis and protects against hypertensive nephropathy. In the heart it improves cardiac function after injury and reduces pathological remodeling. In metabolic disease it improves insulin sensitivity and reduces adipose inflammation. The ACE/ACE2 balance — producing angiotensin II vs angiotensin 1-7 respectively — is a major determinant of cardiovascular risk and has become a key target in hypertension and cardiometabolic therapeutics.
Where does Angiotensin 1-7 sit?
See how this peptide compares across all 85 peptides in our database.
Dosage Information
Typical Dose
Research compound — no established human therapeutic dosing
Frequency
N/A for therapeutic use
Administration
Intravenous or subcutaneous in research
Notes
Several formulations are in clinical trials including inhaled versions for COVID-19 complications. Not currently available as a commercial therapeutic outside of trials.
Compound Data
Molecular Formula
C41H62N12O11
Molecular Weight
899.00 g/mol
IUPAC Name
(2S)-1-[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-carboxypropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]pyrrolidine-2-carboxylic acid
PubChem CID
123805Potential Side Effects
Community Experiences
No experiences shared yet. Be the first!
Quick Facts
- Administration
- Intravenous or subcutaneous in research
- Typical Dose
- Research compound — no established human therapeutic dosing
- Frequency
- N/A for therapeutic use
- References
- 0 curated + 49 from PubMed
- Clinical Trials
- 50 registered
- Evidence Score
- 69.4 / 100